Prime Medicine (PRME) EBITDA (2021 - 2026)

Prime Medicine has reported EBITDA for 6 years, with the latest figure at -$49.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 5.2% year-over-year to -$49.2 million; the trailing twelve-month figure through Mar 2026 stood at -$198.4 million (up 1.77% YoY), and the FY2025 full-year result was -$201.1 million, down 2.65% from the prior year.
• EBITDA for Q1 2026 stood at -$49.2 million, down from -$46.0 million in the prior quarter.
• The five-year high for EBITDA was -$23.8 million in Q1 2022, with the low at -$65.5 million in Q4 2023.
• Historically, EBITDA has averaged -$45.1 million across 5 years, with a median of -$46.0 million in 2025.
• The largest YoY upside for EBITDA was 37.69% in 2022 against a maximum downside of 80.96% in 2022.
• Prime Medicine's EBITDA stood at -$39.2 million in 2022, then plunged by 67.06% to -$65.5 million in 2023, then jumped by 35.43% to -$42.3 million in 2024, then dropped by 8.83% to -$46.0 million in 2025, then decreased by 6.9% to -$49.2 million in 2026.
• The last three EBITDA figures came in at -$49.2 million (Q1 2026), -$46.0 million (Q4 2025), and -$50.5 million (Q3 2025), per Business Quant data.